Bupivacaine veterinary-grade API is distributed as a parenteral-grade active ingredient for injectable solutions and sterile powders for reconstitution. Tablet, capsule, granule, and premix presentations are not supported by published controlled trials in veterinary species and are therefore excluded from the application scenarios below.

The aqueous injectable segment for companion-animal surgical analgesia is built on bupivacaine hydrochloride monohydrate dissolved to final concentrations of 0.25% w/v, 0.5% w/v, and 0.75% w/v, corresponding to 2.5 mg/mL, 5.0 mg/mL, and 7.5 mg/mL. The formula addition ratio is set on a corrected assay basis: 5.0 kg of bupivacaine hydrochloride per 1,000 L of bulk solution yields the nominal 0.5% presentation after density and assay corrections. Sodium chloride is incorporated at 7.5–8.5 mg/mL to maintain osmolality between 284 mOsm/kg and 310 mOsm/kg, and the pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 4.0–6.0. Downstream processing uses 316L stainless-steel formulation vessels, nitrogen sparging to displace oxygen, pre-filtration bioburden control below 10 CFU/100 mL, passage through a 0.45 µm clarifying filter and a 0.22 µm sterilizing-grade PVDF or PES membrane, and aseptic filling on a rotary piston pump line in Grade A with Grade B background under EU GMP Annex 1. Single-dose ampoules are terminally steam-sterilized at 121°C for 12–15 minutes after glass ampoule sealing. Release testing includes USP 71 membrane filtration sterility, USP 85 bacterial endotoxin, USP 788 Method 1 light obscuration particle count, and container closure integrity by USP 1207. Terminal finished-product types are single-dose Type I borosilicate glass ampoules for epidural use and multi-dose rubber-stoppered vials for infiltration analgesia and nerve blocks in dogs and cats where the summary of product characteristics permits preservative-containing presentations.

Can Preservative-Free Epidural Bupivacaine Be Terminally Sterilized Without API Degradation?

Preservative-free bupivacaine 0.25% and 0.5% epidural solutions for horses and cattle are classified as high-risk aqueous parenterals because the absence of antimicrobial preservatives makes the filling stream vulnerable to microbial ingress between sterile filtration and final container closure. The formulation addition is set at 2.5 mg/mL or 5.0 mg/mL bupivacaine hydrochloride with sodium chloride 8.0 mg/mL, hydrochloric acid/sodium hydroxide pH adjustment to 4.5–6.0, and no antimicrobial preservative. Downstream production employs 316L jacketed vessels at 20–25°C, nitrogen blanketing, and double filtration through 0.45 µm and 0.22 µm membranes; terminal moist-heat sterilization at 121°C for 15 minutes is used for 10 mL and 20 mL single-use ampoules. Sterilization validation follows FDA 21 CFR 211.113(b), and the ampoules must meet USP 71 membrane filtration sterility, USP 85 endotoxin, USP 788 particulate matter, and USP 660 Type I glass container requirements. Terminal products include 10 mL and 20 mL preservative-free ampoules for neuraxial, epidural, and regional analgesia in standing equine flank surgery, bovine Cesarean section under extralabel use where local regulatory status permits, and canine hindlimb epidural protocols. The main process constraint is not bupivacaine degradation but closure-mediated contamination risk after autoclaving; any post-sterilization container closure integrity failure triggers revalidation of ampoule sealing temperature, flame intensity, and belt speed.

Equine Perineural and Dental Infiltration Injection Line Requirements Without Antimicrobial Preservatives

Perineural blockade in conscious horses uses low-volume high-precision bupivacaine 0.5% w/v presentations, equivalent to 5.0 mg/mL, packaged in 5 mL single-use syringes or vials without preservative. The formula addition ratio is 5.0 kg bupivacaine hydrochloride monohydrate per 1,000 L bulk solution after assay correction, with 8.0 mg/mL sodium chloride and pH adjusted to 4.0–6.0. The downstream process includes compounding in 316L stainless-steel tanks, chilled dissolution at 18–22°C, nitrogen sparging, pre-filtration through 0.45 µm PVDF, terminal sterile filtration through 0.22 µm PES, and filling into pre-sterilized cyclic olefin polymer syringes using a ceramic pump filler with a 0.22 µm final filter. Terminal sterilization at 121°C for 12–15 minutes is applied after syringe sealing; media fill qualification is repeated every 6 months under EU GMP Annex 1. Terminal products are 5 mL preservative-free syringes and 10 mL vials intended for palmar digital nerve blocks, abaxial sesamoid nerve blocks, and dental infiltration in equine patients that are not declared for the human food chain. Release testing relies on USP 71, USP 85, USP 788, and USP 1207 container closure integrity.

Multivesicular liposome injection for canine postoperative infiltration contains bupivacaine at 13.3 mg/mL, and its production is governed by aseptic manufacturing constraints that preclude terminal sterilization. The lipid-depot formulation uses bupivacaine added at a fixed 13.3 mg/mL base equivalent, with lipid excipients dosed on a millimolar basis and not by simple weight percent. Downstream production consists of high-shear double emulsification, solvent evaporation, and tangential-flow filtration to remove unencapsulated drug; product temperature is maintained at 4–8°C during liposome formation, and the pH is held below 6.2 because higher pH values reduce encapsulation efficiency and alter the multivesicular structure. The suspension is filled aseptically into 10 mL and 20 mL single-use glass vials under EU GMP Annex 1 Grade A conditions. A product-specific particle-size method is used rather than USP 788 because the finished product contains intrinsic lipid particles; release testing includes USP 71 sterility and USP 85 endotoxin. Terminal product types are single-use vials for local infiltration before surgical closure in dogs; the presentation is not indicated for neuraxial, intravascular, or food-producing species use. Production-scale failure modes observed on 50 L and larger batches include sterilizing-filter blinding when the lipid phase has not been pre-filtered through 0.45 µm and 0.22 µm hydrophobic membranes, and batch-to-batch pH drift above 6.2 if the aqueous phase is not cooled before addition to the lipid phase.

If Equine Edible Tissue Entry Is Possible, What MRL and Withdrawal Data Govern the Injectable Line?

Equine injectable bupivacaine products that carry a food-chain authorization are constrained by Commission Regulation (EU) No 37/2010 Annex Table 1, where bupivacaine is listed with marker residue definitions and edible tissue MRLs for equidae. The formulation addition for food-chain compliant presentations is typically 2.5 mg/mL bupivacaine hydrochloride for epidural or local infiltration, with sodium chloride 8.0 mg/mL and pH 4.0–6.0. Downstream production is identical to other aqueous injectables, but the batch record must include residue depletion sampling points from the treated patient model: muscle, fat, liver, and kidney specimens are collected at slaughter after defined withdrawal intervals and analyzed by a validated LC-MS/MS method with a limit of quantification below the MRL. The terminal product types are 10 mL single-dose ampoules and 50 mL multidose vials for equine practice where the horse may enter the human food chain. If a formulation is produced for cattle or sheep where no harmonized EU MRL entry exists, it cannot be marketed as a food-producing-species product in the EU; such batches are restricted to non-food-species use or must follow national cascade residue-control provisions. Release standards remain USP 71 sterility, USP 85 endotoxin, USP 788 particulate matter, and USP 1207 closure integrity. The operational boundary is that withdrawal-period validation is not a batch release test but a pre-authorization residue depletion study; manufacturing sites should retain −20°C stability and residue method validation samples for the entire withdrawal period.

When Commercial Injectable Concentrations Exceed Zoo and Exotic Species Dose Requirements

Zoo and exotic animal practices use lyophilized bupivacaine hydrochloride powder in 2 mL and 5 mL serum vials for extemporaneous reconstitution when commercial 0.25% or 0.5% injections cannot be diluted to the low volumes required for avian, reptile, and small-mammal local infiltration. The powder formulation contains bupivacaine hydrochloride 5.0 mg/mL before lyophilization with mannitol 50 mg/mL as lyoprotectant; after reconstitution with sterile water for injection, final concentrations fall between 0.125% and 0.5% w/v. Downstream production includes dissolution at 20–25°C, filtration through 0.22 µm sterile membranes, aseptic filling into depyrogenated Type I vials, and freeze-drying with primary shelf temperature at −25°C and secondary drying at 20°C for 12 hours. The lyophilized cake is not terminally sterilized after freeze-drying; therefore the complete line from API dissolution through capping must be aseptic, and media fills are qualified every 6 months under USP 797. Terminal products are 2 mL and 5 mL lyophilized vials for local infiltration in non-domestic species and are not labeled for epidural use or food-producing animals. Release testing includes USP 71 sterility of the reconstituted powder, USP 85 endotoxin, USP 788 particulate matter after reconstitution, and Karl Fischer moisture below 1.0% w/w. The primary formulation risk is vial breakage during lyophilization due to thermal stress in 2 mL tubing vials when shelf temperature ramps exceed 0.5°C/min; controlled ramps and partial-stoppering closures are required.